Bristol-Myers Squibb Co. (BMY) News
Filter BMY News Items
BMY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BMY News Highlights
- For BMY, its 30 day story count is now at 23.
- Over the past 15 days, the trend for BMY's stories per day has been choppy and unclear. It has oscillated between 1 and 11.
- AMP, LI and DRUG are the most mentioned tickers in articles about BMY.
Latest BMY News From Around the Web
Below are the latest news stories about BRISTOL MYERS SQUIBB CO that investors may wish to consider to help them evaluate BMY as an investment opportunity.
Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets GoalsCytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response. |
Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study DataBristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively. |
Top 15 Value Stocks to Buy for 2024In this article, we discuss top 15 value stocks to buy for 2024 picked by Joel Greenblatt. To skip the details about Mr. Greenblatt’s life, portfolio performance, and investment strategy, go directly to Top 5 Value Stocks to Buy for 2024. Investing offers an exciting and effective way of growing wealth over time. Value investing is […] |
11 Hot Healthcare Stocks To Buy NowIn this article, we will be taking a look at 11 hot healthcare stocks to buy now. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Hot Healthcare Stocks To Buy Now. Healthcare is a vital part of daily living for everyone, whether it be to cure […] |
Why Is Cytokinetics (CYTK) Stock Up 70% Today?With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest. |
Cytokinetics Stock Skyrockets on Positive Results from Study of Its Heart DrugCytokinetics Inc. reported positive results Wednesday from a key Phase 3 study of its experimental drug to treat heart disease. |
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for LumakrasPer the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval. |
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1BBristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024. |
A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?In pharma, a company can take a larger slice of the healthcare pie than peers, but it is still constrained by the size of the pie. |
Trending tickers: Intel | Tencent | RayzeBio | AstrazenecaThe latest investor updates on stocks that are trending on Wednesday. |